Clinical development failure
Product candidates are early stage and may not demonstrate safety or efficacy in trials.
- Scope
- INM-089, INM-755, INM-901
- Materiality
- high
InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical drug development company focused on proprietary small-molecule candidates for diseases with high unmet medical need. Through its BayMedica subsidiary, it also manufactures and sells bulk rare, non-intoxicating cannabinoids as ingredients for health and wellness applications.
34,5 %
−165,1 %
+7,5 %
6.99
6.47
| % | |
|---|---|
| Pharmaceutical drug candidates | 0% Early-stage proprietary compounds being developed for ocular, dermatology and neurodegenerative indications. |
| Cannabinoid ingredients | 100% Bulk rare cannabinoids manufactured and sold to B2B customers for health and wellness uses. |
| Contracted R&D and development | 0% Research, formulation, CMC and clinical development work supporting pipeline advancement. |
| Manufacturing services and processes | 0% Proprietary and conventional manufacturing approaches used to produce high-purity cannabinoid products. |
InMed’s commercial customers are B2B buyers of rare cannabinoid raw materials, likely including ingredient formulators...
- B2B cannabinoid ingredient buyersprimary
Buy bulk rare, non-intoxicating cannabinoids for use as raw materials in health and wellness products.
- Pharmaceutical licensing partnerssecondary
May license or co-develop INM-755 and other pipeline assets to reduce development risk and fund advancement.
- Clinical and research ecosystemsecondary
CROs, CDMOs, investigators and consultants supporting preclinical and clinical development work.
- Future prescription patientsemerging
Patients with dry AMD, epidermolysis bullosa, itch-related skin conditions and Alzheimer’s disease.
InMed is headquartered in Vancouver, British Columbia, and is listed on Nasdaq in the United States...
- •Headquartered in Vancouver, British Columbia, Canada
- •Listed on Nasdaq Capital Market in the United States
- •Commercial cannabinoid sales are exposed to cross-border trade rules
- •U.S. and Canadian healthcare regulation shapes drug development
- •Manufacturing approach supports flexible sourcing and production
InMed is prioritizing advancement of its proprietary pipeline while keeping BayMedica’s cannabinoid ingredient business...
01
Advance pipeline assets toward clinical and regulatory milestonesmedium-term
Clinical progress is the main path to value creation for a company with no approved products.
02
Monetize BayMedica’s cannabinoid ingredient businessshort-term
Commercial sales provide the only recurring revenue source while the pharma pipeline remains pre-revenue.
03
Pursue strategic partnershipsmedium-term
Partnering can reduce capital intensity and improve the odds of advancing assets like INM-755.
InMed is highly exposed to clinical, regulatory and financing risk because its drug candidates are early-stage and...
Regulatory approval delay or denial
Drug candidates require lengthy and unpredictable FDA/Health Canada review processes.
- Scope
- All pipeline programs
- Materiality
- high
Cannabinoid market and policy change
BayMedica’s commercial inventory and sales depend on the legal treatment of non-intoxicating cannabinoids.
- Scope
- BayMedica commercial business
- Materiality
- high
Financing and going-concern pressure
The company has recurring operating losses and relies on external capital to fund operations.
- Scope
- Corporate liquidity
- Materiality
- high
Nasdaq minimum bid price or listing compliance
Delisting risk can reduce liquidity and access to capital for a small-cap development company.
- Scope
- Common shares on Nasdaq Capital Market
- Materiality
- high
Revenue recognition timing
BayMedica sales and gross margin
Going-concern assessment
Liquidity disclosure and investor perception
Inventory valuation
Cost of sales and asset values
Share-based compensation and warrant valuation
Reported net loss and equity
R&D accrual estimates
Research and development expense
INSMED Inc
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
MARIMED INC.
MRMD · Medicinal Chemicals & Botanical Products
cbdMD, Inc.
YCBD · Perfumes, Cosmetics & Other Toilet Preparations
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
BIOMERICA INC
BMRA · In Vitro & In Vivo Diagnostic Substances
: 28/04/2026